109162 ⎘
Structure or type of the nucleic acid; Chemical structure of the backbone Phosphorothioates
TRANSTHYRETIN (TTR) iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING TTR-ASSOCIATED OCULAR DISEASES
#1202Modified RNAi agents
#1203Nucleic acids for inhibiting expression of TMPRSS6 and iron chelators
#1204Methods and systems for guide RNA design and use
#1205ANTISENSE OLIGONUCLEOTIDES AND THEIR USE FOR TREATING PENDRED SYNDROME
#1206NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF
#1207COMPOSITIONS AND METHODS FOR MODULATING ANGIOPOIETIN-LIKE 3 EXPRESSION
#1208TREATMENT FOR SOD1 ASSOCIATED DISEASE
#1209NUCLEIC ACID, PHARMACEUTICAL COMPOSITION AND CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF
#1210MODULATORS OF YAP1 EXPRESSION
#1211COMPOUNDS AND METHODS FOR REDUCING SNCA EXPRESSION
#1212Nucleic acid-polypeptide compositions and methods of inducing exon skipping
#1213COMPOSITIONS AND METHODS FOR MITIGATION OF ISCHEMIC REPERFUSION INJURY
#1214DELIVERY OF OLIGONUCLEOTIDES TO THE STRIATUM
#1215ANTISENSE RNA EDITING OLIGONUCLEOTIDES COMPRISING CYTIDINE ANALOGS
#1216RNAI CONSTRUCTS FOR INHIBITING SCAP EXPRESSION AND METHODS OF USE THEREOF
#1217Oligonucleotide compositions and methods of making the same
#1218OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF
#1219COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND HBV-TARGETING RNAi
#1220SERUM AMYLOID P COMPONENT (APCS) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
#1221GALNAC CLUSTER PHOSPHORAMIDITE AND TARGETED THERAPEUTIC NUCLEOSIDES
#1222COMPOUNDS AND METHODS FOR MODULATING ANGIOTENSINOGEN EXPRESSION
#1223METHODS FOR TREATING MUSCULAR DYSTROPHY USING INHIBITORY OLIGONUCLEOTIDES TO CD49D
#1224COMPOSITIONS AND METHODS FOR CLL1 MODIFICATION
#1225Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
#1226COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE LECT2 GENE
#1227Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro
#1228Defined multi-conjugates oligonucleotides
#1229Compounds and methods for modulating ATXN1
#1230Nucleic acids for inhibiting expression of LPA in a cell
#1231Products and compositions
#1232COMPOSITIONS AND METHODS FOR MODULATING SPLICING AND PROTEIN EXPRESSION
#1233Muscle targeting complexes and uses thereof for treating dystrophinopathies
#12342'-METHOXY SUBSTITUTED OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATIONS
#1235COMPOSITIONS AND METHODS FOR DETECTING AND TREATING INSULIN RESISTANCE
#1236COMPOUNDS AND METHODS USEFUL FOR MODULATING GENE SPLICING
#1237MOLECULAR TARGETED NUCLEIC ACID MEDICINE FOR GASTRIC CANCER
#1238OLIGONUCLEOTIDE THERAPY FOR STARGARDT DISEASE
#1239COMPOSITIONS AND METHODS FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA
#1240RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (SINA)
#1241COMPOSITIONS AND METHODS FOR MODULATING TTR EXPRESSION
#1242SELECTIVE LOCAL INHIBITION OF TNFR1-MEDIATED FUNCTIONS AT THE SITE OF ANTIGEN/ALLERGEN PRESENTATION
#1243IMMUNOSTIMULATORY SEQUENCE OLIGONUCLEOTIDES AND METHODS OF USING THE SAME
#1244PRODUCTION METHOD FOR BIFURCATED LIPID-LINKED OLIGONUCLEOTIDE, AND INTERMEDIATE
#1245METHODS FOR TREATING OR PREVENTING CONTACT-ACTIVATION PATHWAY-ASSOCIATED DISEASES USING iRNA COMPOSITIONS TARGETING FACTOR XII (HAGEMAN FACTOR) (F12)
#1246SPLICE MODULATING OLIGONUCLEOTIDES TARGETING RECEPTOR FOR ADVANCED GLYCATION END PRODUCTS AND METHODS OF USE
#1247UBE3A ANTISENSE THERAPEUTICS
#1248COMPOUNDS AND METHODS FOR MODULATING TMPRSS6 EXPRESSION
#1249REVERSIR™ compounds
#1250MATERIALS AND METHODS FOR TREATMENT OF HEMOGLOBINOPATHIES
#1251COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF TMPRSS6 GENE
#1252METHOD FOR REDUCING TOXICITY OF ANTISENSE NUCLEIC ACIDS
#1253Enhanced oligonucleotides for inhibiting RTEL1 expression
#1254O-methyl rich fully stabilized oligonucleotides
#1255OLIGONUCLEOTIDE COMPOUNDS FOR TARGETING HUNTINGTIN MRNA
#1256Methods and compositions for inhibiting PMP22 expression
#1257ANGIOTENSIN II TYPE 1 RECEPTOR TARGETED OLIGONUCLEOTIDES AND USES THEREOF
#1258Modulators of Complement Factor B
#1259Modulators of MALAT1 expression
#1260TREATMENT OF HEART FAILURE IN HUMAN SUBJECTS
#1261COMPOUNDS AND METHODS FOR REDUCING FUS EXPRESSION
#1262NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF PROS1 IN A CELL
#1263COMPOSITIONS AND METHODS FOR MODULATING TAU EXPRESSION
#1264RNAi Inhibition of Alpha-ENaC Expression
#1265NUCLEIC ACID, PHARMACEUTICAL COMPOSITION, CONJUGATE, PREPARATION METHOD, AND USE
#1266Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
#1267COMPOSITIONS AND METHODS FOR CD33 MODIFICATION
#1268OLIGONUCLEOTIDE THERAPY FOR WOLMAN DISEASE AND CHOLESTERYL ESTER STORAGE DISEASE
#1269Carboxypeptidase B2 (CPB2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
#1270SERPIN FAMILY F MEMBER 2 (SERPINF2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
#1271OLIGONUCLEOTIDES FOR DGAT2 MODULATION
#1272COMPOUND, METHOD AND PHARMACEUTICAL COMPOSITION FOR MODULATING EXPRESSION OF DUX4
#1273PD-L1 antisense oligonucleotides for use in tumor treatment
#1274NUCLEIC ACID CONJUGATES AND USES THEREOF
#1275COMPLEMENT COMPONENT iRNA COMPOSITIONS AND METHODS OF USE THEREOF
#1276Nucleic acids and methods for the treatment of Pompe disease
#1277ANGPTL2 ANTISENSE OLIGONUCLEOTIDES AND USES THEREOF
#1278ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF USHER SYNDROME
#1279Therapeutic Targeting of a microRNA to Treat Duchenne Muscular Dystrophy
#1280Oral delivery of antisense conjugates targeting PCSK9
#1281MODULATION OF TRANSTHYRETIN EXPRESSION
#1282COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE LECT2 GENE
#1283MODULATION OF APOLIPOPROTEIN C-III (APOCIII) EXPRESSION IN LIPOPROTEIN LIPASE DEFICIENT (LPLD) POPULATIONS
#1284MATERIALS AND METHODS FOR TREATMENT OF HEMOGLOBINOPATHIES
#1285ORAL DELIVERY OF OLIGONUCLEOTIDES
#1286Antisense oligonucleotide for targeting progranulin
#1287Antisense oligonucleotides for the treatment of Stargardt disease
#1288HIGH DENSITY LIPOPROTEIN BINDING PROTEIN (HDLBP/VIGILIN) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
#1289TREATMENT OF GLIAL CELL DERIVED NEUROTROPHIC FACTOR (GDNF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO GDNF
#1290TAU-TARGETING OLIGONUCLEOTIDE GAPMERS
#1291NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF C3 IN A CELL
#1292RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
#1293COMPOUNDS AND METHODS FOR REDUCING ATXN3 EXPRESSION
#1294Compositions for modulating Ataxin 2 expression
#1295OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF
#1296OLIGONUCLEOTIDES AND METHODS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION
#1297Compositions comprising chemically modified guide RNAs for CRISPR/Cas-mediated editing of HBB
#1298CHEMICALLY MODIFIED GUIDE RNAS FOR CRISPR/CAS-MEDIATED GENE CORRECTION
#1299Chemically modified guide RNAS for CRISPR/Cas-mediated gene regulation
#1300METHODS AND COMPOSITIONS FOR INHIBITING EXPRESSION OF CYP27A1
#1301Linkage modified oligomeric compounds and uses thereof
#1302OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF
#1303INTRACELLULAR TARGETING OF MOLECULES
#1304ANTISENSE OLIGONUCLEOTIDES FOR IMMUNOTHERAPY
#1305COMPOUNDS AND METHODS FOR REDUCING KCNT1 EXPRESSION
#1306Modified short interfering nucleic acid (siNA) molecules and uses thereof
#1307ENDOSOMAL CLEAVABLE LINKERS
#1308Oligonucleotides for modulating Tau expression
#1309Antisense Oligonucleotides Targeting ATXN3
#1310AIM2 INHIBITORS AND USES THEREOF
#1311COMPOSITIONS AND METHODS FOR INHIBITING GENE EXPRESSION IN THE CENTRAL NERVOUS SYSTEM
#1312ANTISENSE-INDUCED EXON2 INCLUSION IN ACID ALPHA-GLUCOSIDASE
#1313Modulation of prekallikrein (PKK) expression
#1314Nucleic acids for inhibiting expression of LPA in a cell
#1315Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use
#1316Methods for reducing Ataxin-2 expression
#1317ANGPTL4 oligonucleotides influencing the regulation of the fatty acid metabolism
#1318NUCLEIC ACID COMPLEX FOR MODULATING IHH EXPRESSION
#1319ANTISENSE OLIGOMERS FOR TREATMENT OF CONDITIONS AND DISEASES
#1320ANTISENSE NUCLEIC ACIDS
#1321OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF
#1322Compound for treatment of heart failure
#1323ANTISENSE NUCLEIC ACID TARGETING PCSK9
#1324NOVEL NUCLEIC ACID MOLECULES AND THEIR USE IN THERAPY
#1325HETERO DOUBLE-STRANDED antimiR
#1326ANTISENSE OLIGONUCLEOTIDE-BASED PROGRANULIN AUGMENTATION THERAPY IN NEURODEGENERATIVE DISEASES
#1327Compounds and methods for modulating angiotensinogen expression
#1328Oligonucleotides for inducing paternal UBE3A expression
#1329FRAGILE X MENTAL RETARDATION PROTEIN INTERFERING OLIGONUCLEOTIDES AND METHODS OF USING SAME
#1330TARGETS AND METHODS FOR TREATING EPSTEIN-BARR VIRUS MEDIATED NEURODEGENERATION
#1331OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF
#1332Methods of synthesizing oligonucleotides using tethered nucleotides
#1333Muscle targeting complexes and uses thereof for treating dystrophinopathies
#1334TAU ANTISENSE OLIGOMERS AND USES THEREOF
#1335A DBAIT MOLECULE IN COMBINATION WITH KINASE INHIBITOR FOR THE TREATMENT OF CANCER
#1336NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF PROS1 IN A CELL
#1337OPTIMAL PS MODIFICATION PATTERN FOR HETERONUCLEIC ACIDS
#1338Compositions and methods of treating muscle atrophy and myotonic dystrophy
#1339KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
#1340TREATMENT OF CNS INJURY WITH RNAi THERAPEUTICS
#1341CORONAVIRUS IRNA COMPOSITIONS AND METHODS OF USE THEREOF
#1342OLIGONUCLEOTIDES FOR USE IN THE TREATMENT OF DYSTROPHIC EPIDERMOLYSIS BULLOSA
#1343ANTISENSE OLIGONUCLEOTIDES FOR NUCLEIC ACID EDITING
#1344METHODS AND MATERIALS FOR ACTIVATING AN INTERNAL RIBOSOME ENTRY SITE IN EXON 5 OF THE DMD GENE
#1345REVERSIR TM COMPOUNDS
#1346ANTISENSE OLIGOMERS FOR CONTROLLING CANDIDA ALBICANS INFECTIONS
#1347COMPOSITIONS AND METHODS FOR CORRECTING LIMB GIRDLE MUSCULAR DYSTROPHY TYPE 2C USING EXON SKIPPING
#1348Polycomb-associated Non-Coding RNAs
#1349NOVEL TARGET TO TREAT A METABOLIC DISEASE IN AN INDIVIDUAL
#1350ANGIOPOIETIN-LIKE 3 (ANGPTL3) IRNA COMPOSITIONS AND METHODS OF USE THEREOF
#1351ALPHA-SYNUCLEIN ANTISENSE OLIGONUCLEOTIDES AND USES THEREOF
#1352Modified amine lipids
#1353ANTISENSE OLIGOMERS AND USES THEREOF
#1354RNAi Inhibition of Alpha-ENaC Expression
#1355Modulation of GYS1 expression
#1356CANCER-SPECIFIC MOLECULES AND METHODS OF USE THEREOF
#1357Therapeutic compositions for treating pain via multiple targets
#1358RNA-EDITING OLIGONUCLEOTIDES FOR THE TREATMENT OF USHER SYNDROME
#1359PHOSPHONOACETATE GAPMER OLIGONUCLEOTIDES
#1360COMPOSITIONS COMPRISING SYNTHETIC POLYNUCLEOTIDES ENCODING CRISPR RELATED PROTEINS AND SYNTHETIC SGRNAs AND METHODS OF USE
#1361Antisense Drug Against the Human Intercellular Adhesion Molecule 1 (ICAM-1)
#1362HIGH VISCOSITY MACROMOLECULAR COMPOSITIONS FOR TREATING OCULAR CONDITIONS
#1363SPLICE MODULATING OLIGONUCLEOTIDES AND METHODS OF USE THEREOF
#1364NR2E3 EXPRESSION REDUCING OLIGONUCLEOTIDES, COMPOSITIONS CONTAINING THE SAME, AND METHODS OF THEIR USE
#1365COMPOSITION FOR DELIVERY OF GENETIC MATERIAL
#1366Methods and compositions for editing RNAs
#1367OLIGONUCLEOTIDE
#1368OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF
#1369Methods for Treatment of Alport Syndrome
#1370Methods for Oral Delivery of Oligonucleotides
#1371ANTISENSE OLIGONUCLEOTIDES TARGETING SCN2A RETAINED INTRONS
#1372Gapmer antisense oligonucleotides targeting SARS-CoV-2 for treating COVID 19
#1373Method for generating aptamers with improved off-rates
#1374RNAi Agents for Inhibiting Expression of Alpha-ENaC And Methods of Use
#1375HNF4a saRNA compositions and methods of use
#1376Method of treating fatty liver disease
#1377SPINAL MUSCULAR ATROPHY (SMA) TREATMENT VIA TARGETING OF SMN2 SPLICE SITE INHIBITORY SEQUENCES
#1378OLIGONUCLEOTIDES FOR HTT-1A MODULATION
#1379Complement component C5 iRNA compositions and methods of use thereof
#1380GENETICALLY ENGINEERED T CELLS WITH REGNASE-1 AND/OR TGFBRII DISRUPTION HAVE IMPROVED FUNCTIONALITY AND PERSISTENCE
#1381Bicyclic nucleosides and oligomers prepared therefrom
#1382Genetically engineered T cells with regnase-1 and/or TGFBRII disruption have improved functionality and persistence
#1383Genetically engineered t cells with Regnase-1 and/or TGFBRII disruption have improved functionality and persistence
#1384ANTISENSE OLIGOMERS FOR TREATMENT OF AUTOSOMAL DOMINANT MENTAL RETARDATION-5 AND DRAVET SYNDROME
#1385Compounds and Methods for Use in Dystrophin Transcript
#1386RNAi agents for Hepatitis B virus infection
#1387ANTISENSE OLIGONUCLEOTIDES FOR ALLELE SPECIFICITY
#1388COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING AMYOTROPHIC LATERAL SCLEROSIS
#1389Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
#1390Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
#1391Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
#1392Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
#1393Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
#1394Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
#1395METHODS AND COMPOSITIONS USING RNA INTERFERENCE AND ANTISENSE OLIGONUCLEOTIDES FOR INHIBITION OF KRAS
#1396Allele selective inhibition of mutant C9orf72 foci expression by duplex RNAs targeting the expanded hexanucleotide repeat
#1397ARTIFICIAL NUCLEIC ACIDS FOR RNA EDITING
#1398COMPOUNDS AND METHODS FOR MODULATION OF SMN2
#1399METHODS AND COMPOSITIONS FOR MODULATING ALPHA-1-ANTITRYPSIN EXPRESSION
#1400Nucleic acid-polypeptide compositions and methods of inducing exon skipping
#1401Methods and compositions for treating cancers and enhancing therapeutic immunity by selectively reducing immunomodulatory M2 monocytes
#1402COMPOSITIONS AND METHODS FOR INHIBITING HMGB1 EXPRESSION
#1403MODULATION OF HEPATITIS B VIRUS (HBV) EXPRESSION
#1404SPHERICAL NUCLEIC ACID TLR9 AGONISTS
#1405Double-stranded RNA molecule targeting CKIP-1 and use thereof
#1406Compounds and methods for reducing ATXN2 expression
#1407COMPOUNDS AND METHODS FOR MODULATING SMN2
#1408Compounds and methods for reducing ATXN3 expression
#1409MODIFIED OLIGOMERIC COMPOUNDS AND USES THEREOF
#1410Compositions and methods of treating muscle atrophy and myotonic dystrophy
#1411NUCLEIC ACID, COMPOSITION AND CONJUGATE CONTAINING NUCLEIC ACID, PREPARATION METHOD THEREFOR AND USE THEREOF
#1412COMPOSITIONS AND METHODS FOR THE TREATMENT OF KCNT1 RELATED DISORDERS
#1413RNAi Agents for Inhibiting Expression of 17beta-HSD Type 13 (HSD17B13), Compositions Thereof, and Methods of Use
#1414HBV BINDING OLIGONUCLEOTIDES AND METHODS OF USE
#1415Compounds and methods for modulating PLP1
#1416PROCESS TO INHIBIT OR ELIMINATE EOSINOPHILIC DISEASES OF THE AIRWAY AND RELATED CONDITIONS
#1417METABOLIC BENEFITS OF SHORT MIR-22 MIRNA ANTAGOMIR THERAPIES
#1418RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (SINA)
#1419METHODS AND COMPOSITIONS FOR INHIBITION OF CRISPR RE-CLEAVAGE EVENTS
#1420IMMUNOMODULATING POLYNUCLEOTIDES, ANTIBODY CONJUGATES THEREOF, AND METHODS OF THEIR USE
#1421NEW CONJUGATED NUCLEIC ACID MOLECULES AND THEIR USES
#1422COMPOSITIONS AND METHODS FOR INHIBITION OF EXPRESSION OF APOLIPOPROTEIN C-III (APOC3) GENES
#1423Double-stranded oligonucleotide, composition and conjugate comprising double-stranded oligonucleotide, preparation method thereof and use thereof
#1424MODULATORS OF IRF5 EXPRESSION
#1425SYSTEMS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES
#1426ANTISENSE OLIGONUCLEOTIDES FOR MODULATING HTRA1 EXPRESSION
#1427CONJUGATED OLIGONUCLEOTIDES FOR TISSUE SPECIFIC DELIVERY
#1428APOLIPOPROTEIN C3 (APOC3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
#1429Compositions and their uses directed to huntingtin
#1430INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN, ACID LABILE SUBUNIT (IGFALS) AND INSULIN-LIKE GROWTH FACTOR 1 (IGF-1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
#1431ANTISENSE OLIGONUCLEOTIDES TARGETING CARD9
#1432Compositions and methods of treating muscle atrophy and myotonic dystrophy
#1433Compositions and methods of treating muscle atrophy and myotonic dystrophy
#1434Treatment of thymic stromal lymphopoietin (TSLP) related diseases by inhibition of long-form TSLP transcripts
#1435NEUROFILAMENT PROTEIN FOR GUIDING THERAPEUTIC INTERVENTION IN AMYOTROPHIC LATERAL SCLEROSIS
#1436POLYNUCLEOTIDE AGENTS TARGETING PROGRAMMED CELL DEATH 1 LIGAND 1 (PD-L1) AND METHODS OF USE THEREOF
#1437Compositions and methods for treatment of cardiac diseases
#1438Targeting Ligands
#1439METHODS FOR THE TREATMENT OF TRINUCLEOTIDE REPEAT EXPANSION DISORDERS ASSOCIATED WITH MLH1 ACTIVITY
#1440ENHANCED OLIGONUCLEOTIDES FOR MODULATING FUBP1 EXPRESSION
#1441PRODUCTS AND COMPOSITIONS
#1442Antisense oligomers targeting PCSK9
#1443METHODS FOR TREATMENT OF POLYCYSTIC KIDNEY DISEASE
#1444OLIGOMER-CONJUGATE COMPLEXES AND THEIR USE
#1445BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
#1446Compounds and methods for reducing prion expression
#1447SYSTEMS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES
#1448CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE
#1449RNAI CONSTRUCTS FOR INHIBITING PNPLA3 EXPRESSION AND METHODS OF USE THEREOF
#1450Compositions and methods for treatment of Friedreich's Ataxia
#1451METHODS AND COMPOSITIONS FOR TREATING A SERPINC1-ASSOCIATED DISORDER
#1452NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF C3 IN A CELL
#1453OLIGONUCLEOTIDES CONJUGATES COMPRISING 7'-5'-ALPHA-ANOMERIC-BICYCLIC SUGAR NUCLEOSIDES
#1454Genetically engineered t cells with regnase-1 and/or TGFBRII disruption have improved functionality and persistence
#1455ANGPTL4 oligonucleotides influencing the regulation of the fatty acid metabolism
#1456Compositions and methods of treating muscle atrophy and myotonic dystrophy
#1457Oligonucleotides for treatment of angiopoietin like 4 (ANGPTL4) related diseases
#1458OLIGONUCLEOTIDE INHIBITORS OF NUCLEAR FACTOR KAPPA-LIGHT-CHAIN-ENHANCER OF ACTIVATED B CELLS AND THE USES THEREOF
#1459METHODS OF SAFE ADMINISTRATION OF AN IRF5 ANTISENSE OLIGONUCLEOTIDE
#1460AMYLOID PRECURSOR PROTEIN (APP) RNAi AGENT COMPOSITIONS AND METHODS OF USE THEREOF
#1461NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF LPA IN A CELL
#1462COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE PCSK9 GENE
#1463Compounds and methods for modulation of dystrophia myotonica-protein kinase (DMPK) expression
#1464Specific siRNA molecules, composition and use thereof for the treatment of triple negative breast cancer
#1465POLYNUCLEOTIDE AGENTS TARGETING HYDROXYACID OXIDASE (GLYCOLATE OXIDASE, HAO1) AND METHODS OF USE THEREOF
#1466SiRNA conjugate, preparation method therefor and use thereof
#1467OLIGONUCLEOTIDES TO TREAT EYE DISEASE
#1468PRIMARY CELL GENE EDITING
#1469Splice-switching oligonucleotides and methods of use
#1470METHODS AND COMPOSITIONS FOR TREATMENT OF FRONTOTEMPORAL DEMENTIA
#1471COMPOSITIONS FOR HERPESVIRUS TRANSCRIPTIONAL FEEDBACK CIRCUIT DISRUPTION AND USES THEREOF
#1472RNAI AGENTS FOR HEPATITIS B VIRUS INFECTION
#1473Oligonucleotides for the treatment of nucleotide repeat expansion disorders associated with MSH3 activity
#1474COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION
#1475Compositions and methods for Editing Nucleic Acids in Cells Utilizing Oligonucleotides
#1476METHODS TO IMPROVE POTENCY OF ELECTROPORATION
#1477Compositions and methods for detection of SMN protein in a subject and treatment of a subject
#1478Modulators and modulation of the receptor for advanced glycation end-products RNA
#1479COMPOSITIONS AND METHODS FOR INHIBITION OF EXPRESSION OF PROTEIN C (PROC) GENES
#1480OLIGONUCLEOTIDE FORMULATION METHOD
#1481Oligonucleotide agonists targeting progranulin
#1482MODIFIED DOUBLE STRANDED OLIGONUCLEOTIDE
#1483Dosages and methods for delivering lipid formulated nucleic acid molecules
#1484MODIFIED GUIDE RNAS FOR CRISPR GENOME EDITING
#1485RNA DRUGS AND METHOD OF TREATING AGE-RELATED DISEASE
#148617ß-Hydroxysteroid Dehydrogenase Type 13 (HSD17B13) iRNA Compositions And Methods Of Use Thereof
#1487Compositions and methods for inhibiting ALDH2 expression
#1488Antisense oligonucleotide-based progranulin augmentation therapy in neurodegenerative diseases
#1489Methods and Compositions for the ADAR-Mediated Editing of SERPINA1
#1490MULTIMERIC OLIGONUCLEOTIDES HAVING DECREASED KIDNEY CLEARANCE
#1491The long non-coding RNA INCA1 and Homo sapiens heterogeneous nuclear ribonucleoprotein H1 (HNRNPH1) as therapeutic targets for immunotherapy
#1492CHIRALLY ENRICHED OLIGOMERIC COMPOUNDS
#1493Methods and compositions for treatment of cholesteryl ester storage disease
#1494Multi-Targeting Nucleic Acid Constructs Composed Of Multiple Oligonucleotides That Modulate Gene Expression Through Complimentary Interactions With Targets
#1495OLIGONUCLEOTIDES FOR MODULATING MYH7 EXPRESSION
#1496OLIGONUCLEOTIDES FOR SNCA MODULATION
#1497OLIGONUCLEOTIDES FOR MAPT MODULATION
#1498MODIFIED GUIDE RNAS FOR CRISPR GENOME EDITING
#1499Soluble TNF Receptors and Their Use in Treatment of Disease
#1500COMPOUNDS AND METHODS FOR REDUCING FXI EXPRESSION